Cardio Diagnostics (NASDAQ:CDIO – Get Free Report) and Aurinia Pharmaceuticals (NASDAQ:AUPH – Get Free Report) are both healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, earnings, analyst recommendations, institutional ownership, profitability, dividends and risk.
Institutional and Insider Ownership
8.1% of Cardio Diagnostics shares are held by institutional investors. Comparatively, 36.8% of Aurinia Pharmaceuticals shares are held by institutional investors. 9.0% of Cardio Diagnostics shares are held by insiders. Comparatively, 10.4% of Aurinia Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Volatility & Risk
Cardio Diagnostics has a beta of 2.32, indicating that its stock price is 132% more volatile than the S&P 500. Comparatively, Aurinia Pharmaceuticals has a beta of 1.4, indicating that its stock price is 40% more volatile than the S&P 500.
Profitability
This table compares Cardio Diagnostics and Aurinia Pharmaceuticals’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Cardio Diagnostics | -40,543.75% | -89.41% | -82.81% |
| Aurinia Pharmaceuticals | 97.68% | 22.99% | 17.99% |
Earnings and Valuation
This table compares Cardio Diagnostics and Aurinia Pharmaceuticals”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Cardio Diagnostics | $10,000.00 | 550.56 | -$6.50 million | ($2.53) | -0.74 |
| Aurinia Pharmaceuticals | $321.74 million | 6.79 | $287.20 million | $2.29 | 7.12 |
Aurinia Pharmaceuticals has higher revenue and earnings than Cardio Diagnostics. Cardio Diagnostics is trading at a lower price-to-earnings ratio than Aurinia Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Analyst Ratings
This is a breakdown of recent recommendations for Cardio Diagnostics and Aurinia Pharmaceuticals, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Cardio Diagnostics | 1 | 0 | 0 | 0 | 1.00 |
| Aurinia Pharmaceuticals | 0 | 3 | 2 | 1 | 2.67 |
Aurinia Pharmaceuticals has a consensus price target of $17.33, suggesting a potential upside of 6.34%. Given Aurinia Pharmaceuticals’ stronger consensus rating and higher probable upside, analysts clearly believe Aurinia Pharmaceuticals is more favorable than Cardio Diagnostics.
Summary
Aurinia Pharmaceuticals beats Cardio Diagnostics on 13 of the 15 factors compared between the two stocks.
About Cardio Diagnostics
Cardio Diagnostics Holdings, Inc. is a biotechnology company developing artificial intelligence-powered precision medicine products for the prevention and management of cardiovascular disease. Its approach combines genetic, epigenetic and clinical information to help identify individuals at elevated risk and support more personalized care. The company’s product portfolio includes Epi+Gen CHD, a blood-based test designed to assess an individual’s risk of developing coronary heart disease and provide information that may guide prevention strategies.
About Aurinia Pharmaceuticals
Aurinia Pharmaceuticals Inc. is a biopharmaceutical company focused on developing treatments for autoimmune diseases. The Canadian company’s work has centered on therapies for conditions that can affect the kidneys and other organs. Its lead product, Lupkynis (voclosporin), is an oral medicine approved in the United States to treat adults with active lupus nephritis, a kidney complication of systemic lupus erythematosus. It is used in combination with background immunosuppressive therapy. Aurinia, formerly known as Isotechnika, developed voclosporin as a treatment for lupus nephritis.
Receive News & Ratings for Cardio Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cardio Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.
